ClinConnect ClinConnect Logo
Search / Trial NCT07064525

Evaluate the Efficacy and Safety of SPC1001 Low in Patients With Essential Hypertension

Launched by SHIN POONG PHARMACEUTICAL CO. LTD. · Jul 11, 2025

Trial Information

Current as of July 23, 2025

Enrolling by invitation

Keywords

Blood Pressure Phase 2b Low Dose Combination Therapy Candesartan Amlodipine Indapamide

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Men and women aged 19 to 75 years whose blood pressure measured at the screening visit meets the following criteria.
  • Exclusion Criteria:
  • Patients whose blood pressure measured at the screening and randomization visits meets the criteria of MSSBP ≥180 mmHg or MSDBP ≥110 mmHg, among other conditions.

About Shin Poong Pharmaceutical Co. Ltd.

Shin Poong Pharmaceutical Co., Ltd. is a leading South Korean pharmaceutical company dedicated to the research, development, and commercialization of innovative therapeutic solutions. With a robust pipeline spanning various therapeutic areas, including oncology, infectious diseases, and cardiovascular health, the company is committed to advancing healthcare through cutting-edge research and high-quality products. Leveraging state-of-the-art facilities and a team of experienced professionals, Shin Poong Pharmaceutical aims to address unmet medical needs and improve patient outcomes globally, while adhering to rigorous regulatory standards and ethical practices in clinical trials.

Locations

Seoul, , Korea, Republic Of

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported